Opus Genetics (IRD) versus Its Rivals Head to Head Comparison

Opus Genetics (NASDAQ:IRD) is one of 1,068 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Opus Genetics to related businesses based on the strength of its valuation, institutional ownership, risk, analyst recommendations, profitability, dividends and earnings.

Insider & Institutional Ownership

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 6.6% of Opus Genetics shares are owned by insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Opus Genetics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	0	0	1	0	3.00
Opus Genetics Competitors	8133	21788	49588	1307	2.55

Opus Genetics presently has a consensus target price of $8.00, indicating a potential upside of 633.94%. As a group, “Pharmaceutical preparations” companies have a potential upside of 239.51%. Given Opus Genetics’ stronger consensus rating and higher possible upside, research analysts plainly believe Opus Genetics is more favorable than its rivals.

Earnings and Valuation

This table compares Opus Genetics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Opus Genetics	$19.05 million	-$9.99 million	-1.00
Opus Genetics Competitors	$1.84 billion	$140.61 million	-7.56

Opus Genetics’ rivals have higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Opus Genetics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-324.45%	-63.65%	-56.94%
Opus Genetics Competitors	-3,409.82%	-236.05%	-32.89%

Volatility & Risk

Opus Genetics has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Comparatively, Opus Genetics’ rivals have a beta of 3.66, meaning that their average share price is 266% more volatile than the S&P 500.

Summary

Opus Genetics rivals beat Opus Genetics on 7 of the 13 factors compared.

About Opus Genetics

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.